IP Library Granted Patent US 10,676,746
Granted Patent B2
US 10,676,746 · App. 15/038,342 · Granted Jun 9, 2020

Methods for identifying therapeutic targets and treating monitoring cancers

Inventors: Christopher Kemp (Seattle, WA); Carla Grandori (Seattle, WA); Eduardo Mendez (Seattle, WA); Russell Moser (Seattle, WA); Chang Xu (Mercer Island, WA)
Assignee: Fred Hutchinson Cancer Research Center
C12N15/1137A61K31/407A61K31/426A61K31/4535A61K31/506A61K31/519A61K31/5377A61K31/713A61K33/24A61K45/06C12Q1/6886G01N33/5011C12N2310/14C12Q2600/106C12Q2600/136C12Q2600/156C12Q2600/158G01N2800/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,676,746
App. No.
15/038,342
Granted
Jun 9, 2020
Kind
B2
Abstract

The present invention provides methods for treating cancers having a mutation in one or more tumor suppressor genes, comprising providing to a subject in need thereof an inhibitor of a kinase, as well as related methods and compositions.

Claims (10)

1. A method for treating a pancreatic cancer in a subject in need thereof, wherein the pancreatic cancer comprises a mutation in a Kras gene, the method comprising providing to the subject an inhibitor of NUAK2.

2. The method of claim 1 , wherein the inhibitor inhibits expression of NUAK2.

3. The method of claim 1 , wherein the inhibitor inhibits an activity of NUAK2.

4. The method of claim 1 , further comprising providing to the subject cisplatin.

5. The method of claim 1 , wherein the pancreatic cancer is a primary tumor.

6. The method of claim 1 , wherein the method comprises determining whether the cancer comprises the mutation in the Kras gene before providing the inhibitor to the subject.

7. The method of claim 1 , wherein the method comprises determining a level of expression or activity of NUAK2 or the gene encoding NUAK2 in cancer cells obtained from the subject, before providing the inhibitor of NUAK2 to the subject.

8. The method of claim 1 , wherein the inhibitor comprises a polynucleotide that binds a NUAK2 gene or mRNA.

9. A method for inhibiting the growth and/or proliferation of pancreatic cancer cells comprising a mutation in a Kras gene, comprising contacting the cells with an inhibitor of NUAK2.

10. The method of claim 9 , wherein the inhibitor comprises a polynucleotide that binds a NUAK2 gene or mRNA.

Assignments (3)
MERGER AND CHANGE OF NAME Recorded May 23, 2022
From: FRED HUTCHINSON CANCER RESEARCH CENTER; SEATTLE CANCER CARE ALLIANCE
To: SEATTLE CANCER CARE ALLIANCE
Reel/Frame 060163/0887 →
CHANGE OF NAME Recorded May 23, 2022
From: SEATTLE CANCER CARE ALLIANCE
To: FRED HUTCHINSON CANCER CENTER
Reel/Frame 060389/0005 →
CONFIRMATORY LICENSE Recorded Dec 27, 2016
From: FRED HUTCHINSON CANCER RESEARCH CENTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 041188/0915 →
Continuity (2)
Provisional Application 61907943 · Nov 22, 2013
Related Publication 20160289686A1 · Oct 6, 2016
Cited By (1)
US 12,482,564